At the news
? MIXEDIMPACT 6/10 8-K filed Mar 3, 2026 at 08:31 ET
Atara Biotherapeutics announced that its partner Pierre Fabre Pharmaceuticals has requested a Type A meeting with the FDA to discuss the path forward for tabelecleucel (tab-cel) following a Complete Response Letter for its Biologics License Application. The briefing book submitted includes additional data from the ALLELE study and post-marketing experience in Europe to support potential resubmission.
- Pierre Fabre Pharmaceuticals submitted a request for a Type A meeting with the FDA to address issues raised in the Complete Response Letter for tabelecleucel's BLA issued on January 9, 2026.
- The briefing book includes updated longer-term efficacy data from the ALLELE study, additional supportive data, and post-marketing data from Europe.
- Atara and Pierre Fabre are seeking accelerated approval for EBVALLO (tabelecleucel) for EBV+ PTLD, an ultra-rare disease with high unmet need.
- The FDA previously issued a Complete Response Letter, indicating the application is not approvable in its current form.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access